Hitoshi Kawasaki1, Yasuo Ito1, Chika Kitabayashi1, Ai Tanaka2, Ryoji Nishioka3, Masamizu Yamazato4, Keisuke Ishizawa5, Toshinori Nagai6, Makiko Hirayama1, Kazushi Takahashi1, Toshimasa Yamamoto1, Nobuo Araki7. 1. Department of Neurology, Saitama Medical University, Moroyama, Saitama, Japan. 2. Department of Neurology, Tottori Medical Center, Tottori, Japan. 3. Department of Neurology, Saitama Medical University, Moroyama, Saitama, Japan; Department of Rehabilitation, Inzai General Hospital, Inzai, Chiba, Japan. 4. Department of Neurology, Saitama Medical University, Moroyama, Saitama, Japan; Department of Neurology, Higashimatsuyama Medical Association Hospital, Higashimatsuyama, Saitama, Japan. 5. Department of Neurology, Saitama Medical University, Moroyama, Saitama, Japan; Department of Pathology, Saitama Medical University, Moroyama, Saitama, Japan. 6. Department of Pathology, Saitama Medical University, Moroyama, Saitama, Japan. 7. Department of Neurology, Saitama Medical University, Moroyama, Saitama, Japan. Electronic address: arakin@saitama-med.ac.jp.
Abstract
BACKGROUND: The purpose of this study was to investigate the effects of edaravone on nitric oxide (NO) production, hydroxyl radical (OH-) metabolism, and neuronal nitric oxide synthase (nNOS) expression during cerebral ischemia and reperfusion. METHODS: Edaravone (3 mg/kg) was administered intravenously to 14 C57BL/6 mice just before reperfusion. Eleven additional mice received saline (controls). NO production and OH- metabolism were continuously monitored using bilateral striatal in vivo microdialysis. OH- formation was monitored using the salicylate trapping method. Forebrain ischemia was produced in all mice by bilateral occlusion of the common carotid artery for 10 minutes. Levels of NO metabolites, nitrite (NO2-) and nitrate (NO3-), were determined using the Griess reaction. Brain sections were immunostained with an anti-nNOS antibody and the fractional area density of nNOS-immunoreactive pixels to total pixels determined. RESULTS: Blood pressure and regional cerebral blood flow were not significantly different between the edaravone and control groups. The levels of NO2- did not differ significantly between the 2 groups. The level of NO3- was significantly higher in the edaravone group compared with the control group after reperfusion. 2,3-dihydroxybenzoic acid levels were lower in the edaravone group compared with those in the control group after reperfusion. Immunohistochemistry showed nNOS expression in the edaravone group to be significantly lower than that in the control group 96 hours after reperfusion. CONCLUSIONS: These in vivo data indicate that edaravone may have a neuroprotective effect by reducing levels of OH- metabolites, increasing NO production and decreasing nNOS expression in brain cells.
BACKGROUND: The purpose of this study was to investigate the effects of edaravone on nitric oxide (NO) production, hydroxyl radical (OH-) metabolism, and neuronal nitric oxide synthase (nNOS) expression during cerebral ischemia and reperfusion. METHODS:Edaravone (3 mg/kg) was administered intravenously to 14 C57BL/6 mice just before reperfusion. Eleven additional mice received saline (controls). NO production and OH- metabolism were continuously monitored using bilateral striatal in vivo microdialysis. OH- formation was monitored using the salicylate trapping method. Forebrain ischemia was produced in all mice by bilateral occlusion of the common carotid artery for 10 minutes. Levels of NO metabolites, nitrite (NO2-) and nitrate (NO3-), were determined using the Griess reaction. Brain sections were immunostained with an anti-nNOS antibody and the fractional area density of nNOS-immunoreactive pixels to total pixels determined. RESULTS: Blood pressure and regional cerebral blood flow were not significantly different between the edaravone and control groups. The levels of NO2- did not differ significantly between the 2 groups. The level of NO3- was significantly higher in the edaravone group compared with the control group after reperfusion. 2,3-dihydroxybenzoic acid levels were lower in the edaravone group compared with those in the control group after reperfusion. Immunohistochemistry showed nNOS expression in the edaravone group to be significantly lower than that in the control group 96 hours after reperfusion. CONCLUSIONS: These in vivo data indicate that edaravone may have a neuroprotective effect by reducing levels of OH- metabolites, increasing NO production and decreasing nNOS expression in brain cells.
Authors: Maciej Bladowski; Jakub Gawrys; Damian Gajecki; Ewa Szahidewicz-Krupska; Anna Sawicz-Bladowska; Adrian Doroszko Journal: Oxid Med Cell Longev Date: 2020-08-28 Impact factor: 6.543
Authors: Praveen Kumar Pasala; Rizwaan Abbas Shaik; Mithun Rudrapal; Johra Khan; Mohammad A Alaidarous; Shubham Jagdish Khairnar; Atul R Bendale; Vaishali D Naphade; Ranjan Kumar Sahoo; James H Zothantluanga; Sanjay G Walode Journal: Saudi J Biol Sci Date: 2021-10-08 Impact factor: 4.219
Authors: Nils Korte; Zeki Ilkan; Claire L Pearson; Thomas Pfeiffer; Prabhav Singhal; Jason R Rock; Huma Sethi; Dipender Gill; David Attwell; Paolo Tammaro Journal: J Clin Invest Date: 2022-05-02 Impact factor: 19.456